AC Immune: Q3 Earnings Snapshot

AC Immune SA reported a Q3 loss of $10.8 million, or 16 cents per share, with revenue of $4 million. Shares closed at $2.09, down from $3.18 a year ago, according to the company.

Original reporting
Published Nov 4, 2026, 12:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AC Immune: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$ACIUBearishLow
01

Why it matters

Earnings miss may trigger short covering or opportunistic buying at lower levels.

02

Market read

Micro‑cap biotech earnings miss with limited broader market effect.

03

What to watch

Potential upcoming clinical trial data not mentioned could offset the earnings miss.

Relevance 6/10Novelty 7/10Timing: after-hours

Background

AC Immune SA is a Swiss biopharma focused on neurodegenerative disease therapies.

Company-level read

Ticker impact

$ACIUBearishHigh confidence
Context

Q3 earnings report shows a $10.8M loss and $4M revenue, a fresh disclosure for the biotech.

Expected impact

downward pressure as market prices in the loss

Evidence & confidence

First‑report earnings with a loss and share price decline indicate negative sentiment.

Market effects

Biotech sector may see modest pullback as small‑cap earnings miss adds to sector risk.

Swiss biotech investors could see slight sentiment dip.

Limited impact beyond niche biotech investors.

Counterpoint

The loss may be temporary; pipeline progress could support a rebound.

Key entities

  • AC Immune SA

    Swiss biopharma reporting Q3 loss.

Related articles

$ACIUMedAI 8/10

AC Immune says ACI-7104 shows durable immunogenicity

AC Immune (ACIU) reported positive safety and immunogenicity results for ACI-7104 in a Phase II trial for Parkinson's disease. The study's Part 1 involved 34 patients, with 25 receiving ACI-7104. Shares rose 3.7% to $2.83 on the news. The trial aims to assess safety, tolerability, and immunogenicity in Part 1, and clinical activity in Part 2.

$ACIUHighAI 9/10

AC Immune reports positive phase 2 trial results for ACI-7104

AC Immune (ACIU) reported positive phase 2 trial results for ACI-7104 in early-stage Parkinson’s disease. All 25 patients developed antibodies, with the treatment being safe and well-tolerated. The trial continues with a two-year extension and plans for Part 2. ACI-7104 targets alpha-synuclein protein aggregates, and the company has partnerships worth $4.5B in potential milestones.